BDBM571491 (rac)-4-chloro-(15-rac)-[2-(3,3-difluoropyrrolidin-1-yl)ethyl]-3-ethyl-7-{3-[(6-fluoronaphthalen-1-yl)oxy]propyl}-2-methyl-2,10,11,12,13,15-hexahydropyrazolo[4′,3′:9,10][1,6]oxazacycloundecino[8,7,6-hi]indole-8-carboxylic acid 2-hydroxypropane-1,2,3-tricarboxylic Acid Salt::US11440923, Example 55::US11440923, Example 56::US11440923, Example 57::US11440923, Example 58
SMILES CCc1c-2c(nn1C)C(CCN1CCC(F)(F)C1)OCCCCn1c(C(O)=O)c(CCCOc3cccc4cc(F)ccc34)c3ccc(Cl)c-2c13
InChI Key InChIKey=AGJFZNQFGUFEFK-UHFFFAOYSA-N
Data 10 IC50
Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB
Found 10 hits for monomerid = 571491
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.780nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.840nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 160nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
TargetInduced myeloid leukemia cell differentiation protein Mcl-1 [173-321]/Noxa BH3 Peptide(Human)
Bayer Aktiengesellschaft
US Patent
Bayer Aktiengesellschaft
US Patent
Affinity DataIC50: 0.780nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between MCL-1 and the BH3 domain of Noxa (both human) w...More data for this Ligand-Target Pair
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-XL and the BH3 domain of Bad (both human) w...More data for this Ligand-Target Pair
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-XL and the BH3 domain of Bad (both human) w...More data for this Ligand-Target Pair
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-XL and the BH3 domain of Bad (both human) w...More data for this Ligand-Target Pair